Second Pivotal Trial Supports Lumateperone in Bipolar Mania

Company Johnson & Johnson Innovative Medicine Event Type Phase 3 topline (Study 452) Modality Small molecule (oral atypical antipsychotic) Asset Lumateperone (CAPLYTA) Target 5-HT2A; D2 (proposed) Disease Area Bipolar I disorder, manic or mixed episodes Summary Johnson & Johnson reported November 10 that its second…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *